Key Points
A large, long-term trial of the weight-loss medication Wegovy (semaglutide) found that people tended to lose weight over the first 65 weeks on the drugabout one year and three monthsbut then hit a plateau or set point..
But that early weight loss was generally maintained for up to four years while people continued taking the weekly injections...
The findings, published Monday in Nature Medicine, come from a fresh analysis of data from the SELECT trial, which was designed to look at the drugs effects on cardiovascular health..
Last year, researchers published the trials primary results, which showed that semaglutide reduced participants risk of heart attack, stroke, and cardiovascular-related deaths by 20 percent over the span of a little over three years...
In 2021, researchers published a study in The New England Journal of Medicine showing people on the drug lost 14.9 percent of their weight, while those on a placebo lost 2.4 percenta treatment difference of 12.5 percent...
